Last reviewed · How we verify
levalbuterol tartrate MDI
Levalbuterol tartrate is a long-acting beta2-adrenergic receptor agonist that works by relaxing bronchial muscles to improve airflow to the lungs.
Levalbuterol tartrate is a long-acting beta2-adrenergic receptor agonist that works by relaxing bronchial muscles to improve airflow to the lungs. Used for Maintenance and relief of bronchospasm in asthma and in COPD.
At a glance
| Generic name | levalbuterol tartrate MDI |
|---|---|
| Also known as | Xopenex MDI |
| Sponsor | Sumitomo Pharma America, Inc. |
| Drug class | Long-acting beta2-adrenergic receptor agonist |
| Target | beta2-adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
It does this by binding to and activating the beta2-adrenergic receptors in the bronchial smooth muscle, leading to bronchodilation and improved lung function. This results in improved symptoms of asthma and chronic obstructive pulmonary disease (COPD).
Approved indications
- Maintenance and relief of bronchospasm in asthma and in COPD
Common side effects
- Tremors
- Nervousness
- Headache
- Dizziness
- Palpitations
Key clinical trials
- Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up) (PHASE3)
- Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD (PHASE3)
- A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects (PHASE3)
- Aerosolized Beta-Agonist Isomers in Asthma (PHASE4)
- A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma (PHASE3)
- Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects (PHASE3)
- A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- A Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |